News from Medivir’s ongoing R&D day

Medivir is presenting an R&D update this afternoon on oral herpes project Lipsovir (ME 609) and the company’s protease-based projects on Hepatitis C, osteoporosis and COPD (Chronic Obstructive Pulmonary Disease). A short summary will also be given on the status of the spin out process for the company’s HIV projects, Medivir HIV Franchise AB. LABIAL HERPES Lipsovir - phase III to commence already in July Planning and preparations ahead of the start of phase III clinical trials for Lipsovir (ME 609) have proceeded more quickly and more satisfactorily than previously communicated. This means that the commencement of the clinical trial has been brought forward by several months and will start in July. The aim is to enable a potential market authorization late in 2008. Lipsovir has recently obtained a strengthened and prolonged patent position in the US, extending to 2020. Cathepsin K MIV-701- several clinical indications can be evaluated already next year MIV-701 is a Candidate Drug (CD) which was designated during 2005. As previously advised, the CD will be evaluated in a phase Ia clinical trial early in 2007. Medivir now sees an opportunity and has adopted the goal of pursuing several parallel phase Ib studies: in part against osteoporosis, but also against osteoarthritis (OA) and bone metastases. These two additional therapeutic indications can significantly increase the project’s commercial attractiveness. The phase Ib clinical trials can probably commence during the latter part of 2007. Chronic Obstructive Pulmonary Disease (COPD) – positive efficacy data in a preclinical model Medivir in collaboration with a French research institute has now evaluated Medivir’s advanced COPD compound in a preclinical model for COPD and obtained very positive efficacy data in the model. Medivir’s new protease inhibitor shows a profound and significant efficacy in this disease model and effectively decreased the release of inflammatory biomarkers which are characteristic for COPD. The aim is designate one or more Candidate Drugs (CDs) for further clinical development. The project is on its way into the preclinical optimization phase. FOR ADDITIONAL INFORMATION CONTACT Rein Piir, CFO and VP, Investor Relations +46 708 537292 after 17:00 hours today. The presentations from the R&D day will be made available on Medivir’s website www.medivir.se.